Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Nelson Peltz Pushes for Dupont Split

Simon Wiesenthal Center Honors Rupert Murdoch

Nelson Peltz seems to have the Midas touch. When he buys a stake  in a company, the shares tend to rise. He is an activist investor par excellence, and even when management doesn’t execute on his plans, investors feel more secure buying stocks in a company when Nelson Peltz has its back.

Peltz was behind the hugely successful spin off of Mondelez from Kraft, which created a 78% upside for Kraft. Now Peltz thinks Mondelez should change its name, but who knows if that’s going to happen.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.

Peltz bought a stake in Pepsico, and urged management to split the company up into a beverage and a snack division, but Pepsico said that the two businesses are just fine together, thank you very much. It kind of makes sense that salty snacks would go well with ice cold cola, even though cola sales are down globally.

Now Peltz is trying to convince Dupont to split itself up, and even if Dupont doesn’t, the stock has rose 4% on news that Peltz wanted to see a spinoff because of the company’s underperformance.

Peltz’s Trian fund owns a $1.6 billion stake in the company. Dupont noted that it has seen a 220% appreciation in its stock price since CEO Ellen Coleman took the helm. While Dupont seems to disagree with Peltz’s strategy, it seems to be, at least for now, a polite disagreement.

“Dupont welcomes open communication with shareholders and values input toward our common goal of enhancing shareholder value. We have had a constructive dialogue with Trian.”

Suntrust Robinson Humphrey analyst James Seehan thinks the relationship could be less than amicable. “I think it will take a long time for the two sides to agree on the right corporate strategy, and Trian could be involved in an extended proxy battle.”

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Life-Style Health

Medint’s medical researchers provide data-driven insights to help patients make decisions; It is affordable- hundreds rather than thousands of dollars

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...